Lonza Group AG misses 2025 sales estimates, sees FX headwinds in 2026

Lonza AG

28/01/2026 05:40

Corrects throughout to remove comparison of sales and EBITDA with analyst estimates

Overview

Contract drug manufacturer's 2025 sales grew 21.7% in constant exchange rates (CER)

CORE EBITDA for 2025 rose to CHF 2.1 bln

Company successfully integrated Vacaville site, boosting global manufacturing capabilities

Outlook

Lonza anticipates 2026 CER sales growth of 11-12%

Company expects 2026 CORE EBITDA margin above 32%

Lonza sees FX headwind of -2.0% on sales and EBITDA in 2026

Result Drivers

TECHNOLOGY PLATFORMS - Strong order momentum across Mammalian, Bioconjugates, Small Molecules, Drug Product, and Bioscience supported sales growth

VACAVILLE SITE INTEGRATION - Successful integration of Vacaville site boosted sales, contributing to global manufacturing capabilities

ONE LONZA MODEL - New operating model improved customer experience and operational performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
CHF 6.50 bln
FY Sales Growth
21.70%
FY CORE EBITDA
CHF 2.10 bln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lonza Group AG is CHF670.00, about 20% above its January 27 closing price of CHF558.40

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nEQ9QK775a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)